Form 13-F position report

TRANSMEDICS GROUP INC

Reported by LORD ABBETT & CO LLC

TMDX CUSIP 89377M109 Manager CIK 0000728100

Reported 533,876 shares, up 228,457 (74.8%) from the prior quarter.

Reported value 256.1%; share count 74.8% vs. the prior quarter.

Added
% of reported 13F value 0.26% This manager · Q2 2024
Shares 533,876 Quarter-end amount reported
Reported value $80,412,000 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-09-30 32227000
2022-12-31 73311000
2023-03-31 140410000
2023-06-30 157020000
2023-09-30 36852000
2023-12-31 80947000
2024-03-31 22583000
2024-06-30 80412000
2024-09-30 127034000
2024-12-31 0
2025-06-30 18853000
2025-09-30 14969000
2025-12-31 26383000
2026-03-31 21271000
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for TRANSMEDICS GROUP INC held by LORD ABBETT & CO LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -213,973 (-100.0%) 0 $0 2026-08-14
Q1 2026 Reduced 213,973 -2,900 (-1.3%) 0.07% $21,271,000 2026-05-14
Q4 2025 Added 216,873 +83,459 (62.6%) 0.08% $26,383,000 2026-02-13
Q3 2025 Reduced 133,414 -7,271 (-5.2%) 0.04% $14,969,000 2025-11-13
Q2 2025 New 140,685 +140,685 (0.0%) 0.06% $18,853,000 2025-08-14
Q4 2024 Reduced 0 -809,135 (-100.0%) 0 $0 2025-02-14
Q3 2024 Added 809,135 +275,259 (51.6%) 0.4% $127,034,000 2024-11-14
Q2 2024 Added 533,876 +228,457 (74.8%) 0.26% $80,412,000 2024-08-14
Q1 2024 Reduced 305,419 -720,145 (-70.2%) 0.07% $22,583,000 2024-05-09
Q4 2023 Added 1,025,564 +352,470 (52.4%) 0.28% $80,947,000 2024-02-12
Q3 2023 Reduced 673,094 -1,196,645 (-64.0%) 0.14% $36,852,000 2023-11-13
Q2 2023 Added 1,869,739 +15,656 (0.8%) 0.54% $157,020,000 2023-08-14
Q1 2023 Added 1,854,083 +666,277 (56.1%) 0.51% $140,410,000 2023-05-12
Q4 2022 Added 1,187,806 +415,733 (53.8%) 0.26% $73,311,000 2023-02-10
Q3 2022 New 772,073 +772,073 (0.0%) 0.12% $32,227,000 2022-11-14

Who else reported the position

367 managers reported TRANSMEDICS GROUP INC for Q2 2024.

Managers reporting TRANSMEDICS GROUP INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Reduced 4,490,204 -348,676 0.04% $676,314,550 21 qtrs
BlackRock Inc Added 2,645,558 +121,932 < 0.01% $398,473,949 21 qtrs
VANGUARD GROUP INC Added 2,526,400 +637,306 < 0.01% $380,526,368 21 qtrs
DRIEHAUS CAPITAL MANAGEMENT LLC Added 1,486,073 +202,867 2.17% $223,832,315 9 qtrs
Invesco Ltd Added 1,363,081 +80,348 0.04% $205,307,260 14 qtrs
EVENTIDE ASSET MANAGEMENT LLC Reduced 1,145,430 -24,465 2.95% $172,524,667 5 qtrs
ArrowMark Colorado Holdings LLC Added 1,138,792 +58,866 2.05% $171,524,851 8 qtrs
MACQUARIE GROUP LTD Reduced 956,299 -341,420 0.17% $144,038,000 17 qtrs
STATE STREET CORPORATION Added 782,786 +7,907 < 0.01% $117,903,227 21 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 753,684 +30,246 < 0.01% $113,542,279 21 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
493,003
Shared
0
None
40,873

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.